JP6244591B2 - 新規ピロリジン誘導体及びそれらのアセチルｃｏａカルボキシラーゼ阻害薬としての使用 - Google Patents
新規ピロリジン誘導体及びそれらのアセチルｃｏａカルボキシラーゼ阻害薬としての使用 Download PDFInfo
- Publication number
- JP6244591B2 JP6244591B2 JP2015535002A JP2015535002A JP6244591B2 JP 6244591 B2 JP6244591 B2 JP 6244591B2 JP 2015535002 A JP2015535002 A JP 2015535002A JP 2015535002 A JP2015535002 A JP 2015535002A JP 6244591 B2 JP6244591 B2 JP 6244591B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- och
- mmol
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(CC1NC(C)=*)NC1=O Chemical compound CC(CC1NC(C)=*)NC1=O 0.000 description 10
- HZOJRIFCNTVMCF-UHFFFAOYSA-N CC(COC)(F)F Chemical compound CC(COC)(F)F HZOJRIFCNTVMCF-UHFFFAOYSA-N 0.000 description 2
- ABLYXTNXSACEHE-UHFFFAOYSA-N COCCC(F)F Chemical compound COCCC(F)F ABLYXTNXSACEHE-UHFFFAOYSA-N 0.000 description 2
- FTSJTAIEXFMURW-UHFFFAOYSA-N Brc(c(Br)c1)cc2c1OCCO2 Chemical compound Brc(c(Br)c1)cc2c1OCCO2 FTSJTAIEXFMURW-UHFFFAOYSA-N 0.000 description 1
- ILFHFVYZNIFMLK-UHFFFAOYSA-N C=CCC1(CC(CON)C1)F Chemical compound C=CCC1(CC(CON)C1)F ILFHFVYZNIFMLK-UHFFFAOYSA-N 0.000 description 1
- HSYZCEHTRWCKAM-UHFFFAOYSA-N CC(C1)C1(F)F Chemical compound CC(C1)C1(F)F HSYZCEHTRWCKAM-UHFFFAOYSA-N 0.000 description 1
- IPRXYQXOIIMYQD-UHFFFAOYSA-N CCOCCCF Chemical compound CCOCCCF IPRXYQXOIIMYQD-UHFFFAOYSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- DIIDLVMALWZECQ-UHFFFAOYSA-N COCC(C1)C1(F)F Chemical compound COCC(C1)C1(F)F DIIDLVMALWZECQ-UHFFFAOYSA-N 0.000 description 1
- IIQPGPVBEFHNAW-UHFFFAOYSA-N N#Cc(c(Br)c1)cc2c1OCCO2 Chemical compound N#Cc(c(Br)c1)cc2c1OCCO2 IIQPGPVBEFHNAW-UHFFFAOYSA-N 0.000 description 1
- URKYFRSLKUNMFG-UHFFFAOYSA-N NC(CC1)NC1=O Chemical compound NC(CC1)NC1=O URKYFRSLKUNMFG-UHFFFAOYSA-N 0.000 description 1
- YHNRUSMOYCDMJS-UHFFFAOYSA-N NOCC1CC1 Chemical compound NOCC1CC1 YHNRUSMOYCDMJS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12187591.8 | 2012-10-08 | ||
| EP12187591 | 2012-10-08 | ||
| PCT/EP2013/070507 WO2014056771A1 (en) | 2012-10-08 | 2013-10-02 | New pyrrolidine derivatives and their use as acetyl-coa carboxylase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015531386A JP2015531386A (ja) | 2015-11-02 |
| JP2015531386A5 JP2015531386A5 (Direct) | 2016-11-24 |
| JP6244591B2 true JP6244591B2 (ja) | 2017-12-13 |
Family
ID=47143526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015535002A Expired - Fee Related JP6244591B2 (ja) | 2012-10-08 | 2013-10-02 | 新規ピロリジン誘導体及びそれらのアセチルｃｏａカルボキシラーゼ阻害薬としての使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9169205B2 (Direct) |
| EP (1) | EP2903982B1 (Direct) |
| JP (1) | JP6244591B2 (Direct) |
| WO (1) | WO2014056771A1 (Direct) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6378752B2 (ja) | 2013-05-17 | 2018-08-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピロリジン誘導体、その医薬組成物及び使用 |
| JPWO2015056782A1 (ja) | 2013-10-17 | 2017-03-09 | 塩野義製薬株式会社 | 新規アルキレン誘導体 |
| CA3002144C (en) | 2015-10-16 | 2024-01-23 | Eisai R&D Management Co., Ltd. | Ep4 antagonists |
| KR102224550B1 (ko) * | 2018-04-02 | 2021-03-09 | 울산대학교 산학협력단 | 신규한 에테르 화합물, 및 광 산화환원 촉매를 이용하여 활성화된 알켄 화합물로부터 에테르 화합물을 제조하는 방법 |
| EP4434520A4 (en) | 2021-11-19 | 2025-10-29 | Shionogi & Co | PHARMACEUTICAL PRODUCT FOR THE TREATMENT OF HEART DISEASE OR SKELETAL MUSCLE DISEASE |
| WO2025155669A1 (en) * | 2024-01-17 | 2025-07-24 | The Jackson Laboratory | Trpc3 inhibitors and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1976848A2 (en) | 2005-12-21 | 2008-10-08 | Schering Corporation | Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists |
| US20110166176A1 (en) | 2008-02-22 | 2011-07-07 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
| US9006450B2 (en) | 2010-07-01 | 2015-04-14 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| WO2012090219A2 (en) | 2010-12-31 | 2012-07-05 | Jubilant Biosys Ltd. | Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors |
-
2013
- 2013-10-01 US US14/043,128 patent/US9169205B2/en active Active
- 2013-10-02 EP EP13771485.3A patent/EP2903982B1/en active Active
- 2013-10-02 WO PCT/EP2013/070507 patent/WO2014056771A1/en not_active Ceased
- 2013-10-02 JP JP2015535002A patent/JP6244591B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US9169205B2 (en) | 2015-10-27 |
| WO2014056771A1 (en) | 2014-04-17 |
| EP2903982B1 (en) | 2016-12-28 |
| EP2903982A1 (en) | 2015-08-12 |
| JP2015531386A (ja) | 2015-11-02 |
| US20140100211A1 (en) | 2014-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6130398B2 (ja) | 新規アゼチジン誘導体、その医薬組成物及び使用 | |
| JP6130399B2 (ja) | 新規アゼチジン誘導体、医薬組成物およびそれらの使用 | |
| JP5654675B2 (ja) | ピペリジン誘導体及び代謝障害の治療のためのそれらの使用 | |
| JP6048406B2 (ja) | 新規化合物、医薬組成物及びこれらの使用 | |
| JP6047825B2 (ja) | ピロリジン誘導体、その医薬組成物及び使用 | |
| JP2015531386A (ja) | 新規ピロリジン誘導体及びそれらのアセチルｃｏａカルボキシラーゼ阻害薬としての使用 | |
| JP5928737B2 (ja) | エチン誘導体、医薬組成物及びその使用 | |
| JP6446433B2 (ja) | ピリミジン置換ピロリジン誘導体、医薬組成物及びこれらの使用 | |
| JP6378752B2 (ja) | ピロリジン誘導体、その医薬組成物及び使用 | |
| JP6559228B2 (ja) | 肥満症及び糖尿病の治療に有用なテトラヒドロイソキノリン誘導体及び医薬組成物 | |
| JP6098001B2 (ja) | 新規ピペリジン誘導体、その医薬組成物及び使用 | |
| JP6129199B2 (ja) | ピペリジン誘導体、その医薬組成物及び使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161003 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161003 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170710 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170713 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171010 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171018 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171025 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6244591 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |